Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2000-06-23
2002-08-20
Rotman, Alan L. (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C546S303000
Reexamination Certificate
active
06437139
ABSTRACT:
FIELD OF INVENTION
This invention relates to the manufacture of intermediates suitable for use in the manufacture of Omeprazole and other medicines and the use thereof to manufacture Omeprazole and other medicines. This invention in its broadest aspects is directed to the manufacture of intermediates useful in the manufacture of medicines such as Omeprazole, Pantoprazole, and Lansoprazole, intermediates suitable for the use to manufacture medicines and the processes for manufacturing the intermediates and for using those intermediates to manufacture medicines.
BACKGROUND OF INVENTION
The reported synthesis of Omeprazole basically involves the coupling of intermediates A and B to form intermediate C which is oxidized to the sulfinyl or sulfoxy compound, Omeprazole.
(See for example Canadian Letters Patent No. 1,127,158 Hassle)
Hassle used the N-oxide form of intermediate A:
(See Canadian Letters Patent No. 1,234,118)
The N-Oxide form may be considered necessary to prepare the precursor 4-nitro compound and it is essential for the alkylation/functionalization of the 2-position (X), according to Hassle's process. Intermediate A (N-Deoxygenated) is then coupled with intermediate B on the route to Omeprazole.
Esteve, on the other hand, described a synthesis that involves coupling the N-oxides of the 4-nitro or the 4-Chloro with intermediate B to form the N-Oxide of intermediate C. Following that, Esteve either substituted at the pyridinyl 4-position with the methoxy and then reduced the N-Oxide or vice-versa.
R
2
: —Cl, —NO
2
, or —OCH
3
(See European Patent No. 484,265)
Torcan, reported a method that offers advantages involving the oxidation and the purification of the final product. Their method comprises oxidizing the amide of Intermediate C to the corresponding amide sulfinyl compound followed by hydrolysis and decarboxylation to form Omeprazole. Torcan did not report processes for the manufacture of the pyridinyl moiety.
(See U.S. Pat. No. 5,374,730)
Other Oxidation methods used for converting the thioether “Intermediate C” to the sulfinyl are purportedly taught by recent Takeda (CA 1,263,119) and Hassle's (U.S. Pat. No. 5,386,032) patents.
C. L. Pharma's U.S. Pat. No. 5,066,810 teaches a process to manufacture
where X is OH or Cl by catalytic hydrogenation of 3,5-dimethyl-4-methoxy-2-cyanopyridine as depicted below
in the presence of an inert diluent, the resulting 3,5-dimethyl-4-methoxy-2-aminomethylpyridine as depicted below
which is then reacted with sodium nitrite in aqueous-acidic solution to give 3,5-dimethyl-4-methoxy-2-hydroxymethylpyridine and ultimately reacting the latter with thionyl chloride to give 3,5-dimethyl-4-methoxy-2-chloromethylpyridine.
In European Patent Publication No. 0103553 and in Canadian Letters Patent 1,234,118 and in U.S. Pat. Nos. 4,544,750 and 4,620,008, the following synthetic route for the pyridine part of omeprazole is described:
More recently, a method for the synthesis of intermediate A was published by a Taiwanese group. This procedure consisted of preparation of the pyrone, pyridone and pyridine derivatives that can be converted to intermediate A. (Heterocycles, 45, 1997, 77).
There are certain disadvantages associated with the current manufacturing processes, largely derived from the N-Oxide intermediates. Nitropyridines and their N-oxides are suspected carcinogens and therefore are unsafe to handle. Also, the above processes employ the nitropyridines and their N-oxides in the early or late stages of the manufacture. In both cases the suspected carcinogens are potential impurities.
While the Taiwanese method does not employ nitropyridines or N-oxides, it suffers from the disadvantage that it employs a large number of steps (approximately 10 steps) and the low availability of the starting material. Both are factors that affect the manufacturing yield and cost.
It is therefore an object of the invention to provide a method of manufacturing intermediates useful in preparing medicines where said intermediates avoid N-oxides that are suspected carcinogens.
It is also another object of the invention to provide methods of manufacturing intermediates useful in preparing medicines where said method employs intermediates that are safe to handle.
It is also another object of the invention to provide methods of manufacturing intermediates useful in preparing medicines wherein the number of steps are minimal in number.
It is also another object of the invention to provide methods of manufacture which incorporate materials that are readily available.
Further and other objects of the invention will be realized by those skilled in the art from the following summary of the invention.
SUMMARY OF THE INVENTION
According to one aspect of the invention, there is provided a process of making Compound III (shown hereafter) by reacting a compound of the formula II
with an organic free radical .R
4
(for example prepared in situ) to produce the compound of formula III
wherein
R
1
=H or CH
3
R
2
=H or CH
3
R
3
=Alkoxy (1-4C), OCH
2
CF
3
, Cyano, Hydrogen, Halogen, Acetoxy or Aryloxy, any electron withdrawing group or salts (organic or inorganic) of electron donating groups
R
4
=Alkyl, Acyl (ketone), Amides (carbamoyl), Alkoxycarbonyl (COOR
1
, R
1
=(1-3C)), Aryloxycarbonyl, Carboxylic Acid, Aryloxymethyl (—CH
2
OAr), Phenoxymethyl, Hydroxymethyl (—CH
2
OH)
or an obvious chemical equivalent. (The source of R
4
may be any suitable compound.)
According to another aspect of the invention, there is provided a process of producing a compound of formula I′
using intermediate III. An exemplary process may be by carrying out the following reaction step or steps which are obvious chemical equivalents of the following steps:
According to another aspect of the invention, there is provided a process of manufacturing Omeprazole by using the intermediate formed by the process above described with the appropriate substituents or an obvious chemical equivalent.
According to another aspect of the invention, there is provided a process of manufacturing Pantoprazole by using the intermediate formed by the process above described with the appropriate substituents or an obvious chemical equivalent.
According to another aspect of the invention, there is provided a process of manufacturing Lansoprazole by using the intermediate formed by the process above described with the appropriate substituents or an obvious chemical equivalent.
According to another aspect of the invention, there is provided a process of forming a compound having the structure
by reacting a compound having the structure
R
1
, R
2
and R
3
as previously defined, with a radical .alkyl under free radical reaction conditions or an obvious chemical equivalent.
According to another aspect of the invention, there is provided a process of forming a compound having the structure
by reacting a compound having the structure
R
1
, R
2
and R
3
as previously defined, with a radical .acyl under free radical reaction conditions or obvious chemical equivalent.
According to another aspect of the invention, there is provided a process of forming a compound having the structure
by reacting a compound having the structure
R
1
, R
2
and R
3
as previously defined, with a radical .amide under free radical reaction conditions or obvious chemical equivalent.
According to another aspect of the invention, there is provided a process of forming a compound having the structure
by reacting a compound having the structure
R
1
, R
2
and R
3
as previously defined, with a radical .alkoxycarbonyl under free radical reaction conditions or obvious chemical equivalent.
According to another aspect of the invention, there is provided a process of forming a compound having the structure
by reacting a compound having the structure
R
1
, R
2
and R
3
as previously defined, with a radical .aryloxycarbonyl under free radical reaction conditions or obvious chemical equivalent.
According to another aspect of the invention, there is provided a process of forming a compound
Chen Liquin
Zoghbi Michel
Covington Raymond
Hughes Ivor M.
Hughes Neil H.
PDi-Research Laboratories, Inc.
Rotman Alan L.
LandOfFree
Synthesis of pharmaceutically useful pyridine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthesis of pharmaceutically useful pyridine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthesis of pharmaceutically useful pyridine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2933003